Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.

M Ighilahriz,M Benfodda,H Sharpe,N Soufir,S Mourah,N Dumaz,M Battistella,A Savina, F Bouquet,S Nikolaev,N Basset-Seguin

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY（2019）

引用 2|浏览18

暂无评分

摘要

Hedgehog pathway inhibitors (HPI) inactivating SMO , have become first line treatment for patients with locally advanced BCC (laBCC). HPI safety and efficacy have been shown in clinical trials . Nevertheless, common adverse events lead to treatment discontinuation. This article is protected by copyright. All rights reserved.

查看译文

关键词

Basal cell carcinoma,SMO mutations,multifocal relapses,resistance,vismodegib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要